Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00895310 · ClinicalTrials.gov registry record · Phase 2

Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy

A Phase 2 study, sponsored by University of California, Davis.

Completed
Registry status
Phase 2
Development phase
30
Enrollment target

NCT00895310 is a Phase 2 study that has completed, run by University of California, Davis. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00895310, a Phase 2 study, has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
Phase 2
Development phase
30 participants
Enrollment target

Study Summary

The purpose of this study is to test the safety of ketoconazole and how well it works after chemotherapy has been used. Ketoconazole at lower doses has been used for fungal infections however has not yet been approved by the Food and Drug Administration for use in prostate cancer. Ketoconazole has been used for many years at high doses for prostate cancer, and this study will be to look at use of lower dose ketoconazole after someone has received chemotherapy. Ketoconazole works by halting the production of steroids in your body, including testosterone, and is thought to work directly on prostate cancer cells in published lab studies.

Interventions

  • DRUG Hydrocortisone
  • DRUG Ketoconazole

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2009-05
Est. Completion 2015-05
Phase Phase 2

Sponsor

University of California, Davis

657 total trials

What the Registry Record Tells You About NCT00895310

The ClinicalTrials.gov registry entry for NCT00895310 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Hydrocortisone is the first listed.

NCT00895310 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00895310 about?

NCT00895310 is a clinical study titled "Use of Low Dose Ketoconazole in Prostate Cancer That Does Not Respond to Hormone Therapy and Prior Chemotherapy". The purpose of this study is to test the safety of ketoconazole and how well it works after chemotherapy has been used. Ketoconazole at lower doses has been used for fungal infections however has not yet been approved by the Food and Drug Administration for use in prostate cancer. Ketoconazole has b...

What is the current status of trial NCT00895310?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2009-05. Estimated completion is 2015-05.

What interventions are being tested in trial NCT00895310?

The interventions under investigation include: Hydrocortisone (DRUG), Ketoconazole (DRUG).

Who is sponsoring clinical trial NCT00895310?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.